SCHEMBL1688829

SCHEMBL1688829

CC(=O)N(C)c1cc(-c2ccnc3c(C#N)cnn23)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.58
GABRA1 P14867 2/20 0.58
GABRG2 P18507 2/20 0.58
GABRB3 P28472 2/20 0.58
MAPK1 P28482 2/20 0.58
GABRA2 P47869 1/20 0.58
GABRB2 P47870 1/20 0.58
AOX1 Q06278 1/20 0.58
PDE3A Q14432 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 4/20 0.51
HPGD P15428 2/20 0.51
CLK4 Q9HAZ1 1/20 0.51
EGLN2 Q96KS0 5/20 0.48
MDM2 Q00987 1/20 0.41
TLR8 Q9NR97 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
KDM4D Q6B0I6 1/20 0.37
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1688826 0.88 KDM4E (0.58) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL1688835 0.84 SMN1; SMN2 (0.52) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL3161983 0.82 KDM4E (0.77) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL29530755 0.82 KDM4E (0.77) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL2108181 0.81 NTRK1 (0.57) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL1688817 0.81 KDM4E (0.41) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL2615315 0.78 KDM4E (0.58) KDM4EGABRA1GABRG2GABRB3MAPK1
Lorediplon SCHEMBL1316601 0.77 CDKN1A (0.54) KDM4EGABRA1GABRG2GABRB3MAPK1
Lorediplon SCHEMBL29376531 0.77 CDKN1A (0.54) KDM4EGABRA1GABRG2GABRB3MAPK1
SCHEMBL3167714 0.76 KDM4E (0.71) KDM4EGABRA1GABRG2GABRB3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158632-B2 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2012-04-17 US claimed
EP-2059521-B1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2010-06-02 EP claimed
US-20090264448-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INTERNATIONAL, S.A. (ES) 2009-10-22 US claimed
EP-2059521-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-05-20 EP claimed
WO-2008015253-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2008-02-07 WO claimed
EP-1884516-A1 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-06 EP claimed
US-8158632-B2 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2012-04-17 US disclosed
EP-2059521-B1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2010-06-02 EP disclosed
US-20090264448-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INTERNATIONAL, S.A. (ES) 2009-10-22 US disclosed
EP-2059521-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-05-20 EP disclosed
WO-2008015253-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2008-02-07 WO disclosed
EP-1884516-A1 Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264448-A1 PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS P2RX5, GABRA5, P2RX1 KDM4E 740/4885GABRA1 8/4885GABRG2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.